Emisphere Technologies, Inc. Announces Second Quarter 2014 Earnings Conference Call
ROSELAND, N.J., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company") announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended June 30, 2014 on Thursday, August 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening.
The live webcast of the conference call can be accessed through the Company's web site at: www.emisphere.com. The live conference call dial-in number is 1 (877) 303-9483 (United States and Canada) or 1 (760) 666-3584 (International). In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning at 1:00 PM ET on August 14, 2014 through 11:59 PM ET on August 28, 2014 by calling 1 (855) 859-2056 (United States and
Canada) or 1 (404) 537-3406 (International). The conference replay PIN is 83149973.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a specialty pharmaceutical company that has been transformed from a delivery systems development company into a broader commercial-stage entity. Assuming the Company is successful in securing necessary funding, of which there can be no assurance, it plans to commence its launch efforts for its first commercial product, oral Eligen® B12 Rx, during the remainder of 2014. Oral Eligen® B12 Rx meets significant unmet patient and medical needs by combining B12 with our proprietary delivery system technology. All key oral Eligen® B12 Rx launch initiatives are in progress and on schedule introduce the Eligen® B12 in the United States during the first quarter 2015. Additionally, the Company is
currently engaged in multiple late-stage ex-US oral Eligen® B12 Rx licensing discussions. By building on the oral Eligen® B12 Rx product, the Company intends to establish a sound product portfolio platform on which to expand its B12 therapeutic franchise as well as expand internal new product development with new therapeutic agents. The Company will also continue to develop its existing drug delivery carrier partnerships and expand its carrier business by seeking out and engaging in new global licensing opportunities. The Company's strategy is to reemphasize the commercialization of oral Eligen® B12 Rx, build new high-value partnerships, evaluate new commercial opportunities, and promote new uses for the Eligen® Technology. The Company's website is: www.emisphere.com.
CONTACT: For further information contact:
Alan L. Rubino - CEO
973.532.8100 or firstname.lastname@example.org
Michael R. Garone - CFO
973.532.8005 or email@example.com
Source: Emisphere Technologies, Inc.
News Provided by Acquire Media